I'm LongbridgeAI, I can summarize articles.Silo Pharma received a Canadian Notice of Allowance for its patent application covering SPC-15, an intranasal 5-HT4 receptor agonist for PTSD. The patent protects the prophylactic use of these agonists to prevent stress-induced fear and depressive behaviors. Silo holds exclusive global rights from Columbia University and plans to pursue the FDA’s 505(b)(2) pathway to accelerate development.
- Silo Pharma received a Canadian Notice of Allowance for a patent application covering SPC-15, an intranasal 5-HT4 receptor agonist for PTSD. * The application covers prophylactic use of 5-HT4 agonists to prevent or delay stress-induced fear and depressive-like behavior. * Silo holds an exclusive license from Columbia University to develop, manufacture, and commercialize SPC-15 globally. * The company plans to pursue the FDA’s 505(b)(2) pathway for SPC-15 to shorten development timelines and cut costs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608181615PRIMZONEFULLFEED9812252) on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)